
AstraZeneca has revealed new data for Fasenra (benralizumab), demonstrating that patients using the drug can “achieve near-complete depletion of eosinophils …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

